### Ondansetron

**Section:** 2. Medicines for pain and palliative care > 2.3. Medicines for other common symptoms in palliative care

**Indication** | Palliative care   | ICD11 code: QC7A
---|---|---
**INN** | Ondansetron
**Medicine type** | Chemical agent
**List type** | Core
**Formulations** | Parenteral > General injections > IV: 2 mg per mL in 2 mL ampoule (ondansetron base, as hydrochloride)
Oral > Liquid: 4 mg per 5 mL (ondansetron base)
Oral > Solid: 4 mg (ondansetron base) ; 8 mg (ondansetron base)
**EML status history** | First added in 2011 (TRS 965)
Changed in 2019 (TRS 1021)
Changed in 2021
**Sex** | All
**Age** | Also recommended for children
**Age restriction** | > 1 month
**Therapeutic alternatives** | dolasetron (ATC codes: A04AA04)
granisetron (ATC codes: A04AA02)
palonosetron (ATC codes: A04AA05)
tropisetron (ATC codes: A04AA03)
**Patent information** | Patents have expired in most jurisdictions
Read more about patents.
**Wikipedia** | Ondansetron
**DrugBank** | Ondansetron

---

**Summary of evidence and Expert Committee recommendations**

Following the review of square box listings on the EML and EMLc, the Expert Committee recommended that dolasetron, granisetron, palonosetron and tropisetron be specified as therapeutic alternatives under the square box listing for ondansetron on the EML and EMLc.